Quick Answer
Intellia Therapeutics, Inc. reported Diluted EPS of $3.81 per share (loss) for fiscal year 2025.
Intellia Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.81 | +27.4% |
| 2024 | -$5.25 | +3.1% |
| 2023 | -$5.42 | +12.0% |
| 2022 | -$6.16 | -63.0% |
| 2021 | -$3.78 | -57.5% |
| 2020 | -$2.40 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.92 | +31.3% | +6.1% |
| June 30, 2025 | -$0.98 | +35.5% | +10.9% |
| March 31, 2025 | -$1.10 | +1.8% | +17.9% |
| September 30, 2024 | -$1.34 | +2.9% | +11.8% |
| June 30, 2024 | -$1.52 | -8.6% | -35.7% |
| March 31, 2024 | -$1.12 | +4.3% | +18.8% |
| September 30, 2023 | -$1.38 | +7.4% | +1.4% |
| June 30, 2023 | -$1.40 | -5.3% | -19.7% |
- Intellia Therapeutics, Inc. showed an increase of +27.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Intellia Therapeutics, Inc.’s diluted eps has declined by 58.8% (from $2.40 per share (loss) to $3.81 per share (loss)).
- The most recent figure is from Intellia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: